Mog (35-55) Chemical Properties

Density 

1.48±0.1 g/cm3(Predicted)

storage temp. 

-15°C

solubility 

≥32.25 mg/mL in H2O; insoluble in EtOH; ≥86 mg/mL in DMSO

form 

solid

Water Solubility 

Soluble to 0.50 mg/ml in water

Sequence

H-Met-Glu-Val-Gly-Trp-Tyr-Arg-Ser-Pro-Phe-Ser-Arg-Val-VAL-His-Leu-Tyr-Arg-Asn-Gly-Lys-OH

InChI

InChI=1/C118H177N35O29S/c1-61(2)47-80(103(169)143-81(49-66-30-34-70(156)35-31-66)104(170)139-75(26-17-42-129-116(122)123)99(165)145-86(53-90(121)158)98(164)133-56-91(159)136-79(115(181)182)25-15-16-41-119)142-108(174)85(52-69-55-128-60-135-69)147-112(178)95(63(5)6)152-113(179)96(64(7)8)151-101(167)77(28-19-44-131-118(126)127)141-109(175)87(58-154)148-106(172)83(48-65-21-11-10-12-22-65)146-110(176)89-29-20-45-153(89)114(180)88(59-155)149-100(166)76(27-18-43-130-117(124)125)140-105(171)82(50-67-32-36-71(157)37-33-67)144-107(173)84(51-68-54-132-74-24-14-13-23-72(68)74)137-92(160)57-134-111(177)94(62(3)4)150-102(168)78(38-39-93(161)162)138-97(163)73(120)40-46-183-9/h10-14,21-24,30-37,54-55,60-64,73,75-89,94-96,132,154-157H,15-20,25-29,38-53,56-59,119-120H2,1-9H3,(H2,121,158)(H,128,135)(H,133,164)(H,134,177)(H,136,159)(H,137,160)(H,138,163)(H,139,170)(H,140,171)(H,141,175)(H,142,174)(H,143,169)(H,144,173)(H,145,165)(H,146,176)(H,147,178)(H,148,172)(H,149,166)(H,150,168)(H,151,167)(H,152,179)(H,161,162)(H,181,182)(H4,122,123,129)(H4,124,125,130)(H4,126,127,131)/t73-,75-,76-,77-,78-,79-,80-,81-,82-,83-,84-,85-,86-,87-,88-,89-,94-,95-,96-/s3

InChIKey

JMTCEFUSRHYJBF-LTFOILMJNA-N

SMILES

N1(CCC[C@H]1C(=O)N[C@@H](CC1C=CC=CC=1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1C=CC(=CC=1)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CCCCN)C(O)=O)CC(N)=O)C(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC1C=CC(=CC=1)O)NC(=O)[C@@H](NC(CNC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(O)=O)NC([C@H](CCSC)N)=O)=O)CC1C2C=CC=CC=2NC=1 |&1:4,8,19,25,36,43,50,60,68,80,91,99,114,120,131,143,150,157,165,r|

Mog (35-55) Usage And Synthesis

Description

MOG (35-55) or myelin oligodendrocyte glycoprotein (MOG) 35-55 is a minor component of CNS myelin. MOG (35-55) produces a relapsing-remitting neurological disease with extensive plaque-like demyelination, common to the manifestations of multiple sclerosis. MOG (35-55) induces strong T and B cell responses and is highly encephalitogenic. MOG (35-55) induces T cell-mediated multiple sclerosis in animal models. When co-administered with ITE, MOG (35-55) induces tolerogenic dendritic cells and suppresses disease development in mouse preclinical models of multiple sclerosis.

Uses

Mog (35-55) can be used as an antigen immunized C57BL/6J mice to induces severe chronic experimental autoimmune encephalomyelitis in transgenic mice.

Biological Activity

mog (35-55) is a truncated peptide derived from the human myelin oligodendrocyte glycoprotein (mog). mog, a member of the immunoglobulin superfamily, is expressed wildly in the central nervous system. in mouse and rat models for human multiple sclerosis, mog is involved in inducing the experimental autoimmune encephalomyelitis. humoral auto-immunity to the myelin oligodendrocyte glycoprotein (mog) may be associated with the pathogenesis of multiple sclerosis (ms) [1].mog (35-55) is involved in inducing autoantibody production and relapsing-remitting neurological disease causing extensive plaque-like demyelination [2]. in hla-dr2-transgenic mice, myelin oligodendrocyte glycoprotein-35-55 peptide induced severe chronic experimental autoimmune encephalomyelitis [3].mog35-55 was highly encephalitogenic and could induce strong t and b cell responses in rats [4]. in nod/lt mice (h-2g7) and c57bl/6 mice (h-2b), single injection of mog35-55 in cfa could induce ms-like disease [4].

storage

Store at -20°C

References

[1]. de march a k, de bouwerie m, kolopp-sarda m n, et al. anti-myelin oligodendrocyte glycoprotein b-cell responses in multiple sclerosis[j]. journal of neuroimmunology, 2003, 135(1): 117-125.
[2]. slavin a, ewing c, liu j, et al. induction of a multiple sclerosis-like disease in mice with an immunodominant epitope of myelin oligodendrocyte glycoprotein[j]. autoimmunity, 1998, 28(2): 109-120.
[3]. rich c, link j m, zamora a, et al. myelin oligodendrocyte glycoprotein‐35–55 peptide induces severe chronic experimental autoimmune encephalomyelitis in hla‐dr2‐transgenic mice[j]. european journal of immunology, 2004, 34(5): 1251-1261.
[4]. slavin a, ewing c, liu j, et al. induction of a multiple sclerosis-like disease in mice with an immunodominant epitope of myelin oligodendrocyte glycoprotein[j]. autoimmunity, 1998, 28(2): 109-120.

Mog (35-55)(149635-73-4)Related Product Information

• H-HIS-CYS-LEU-GLY-LYS-TRP-LEU-GLY-HIS-PRO-ASP-LYS-PHE-OH
• PLP (139-151)
• Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat (TFA)
• BIOT-MEVGWYRSPFSRVVHLYRNGK-OH
• Mog (35-55)